Comparative Pharmacology
Head-to-head clinical analysis: QUETIAPINE FUMARATE versus REXULTI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUETIAPINE FUMARATE versus REXULTI.
QUETIAPINE FUMARATE vs REXULTI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antagonist at serotonin 5-HT2A, dopamine D2, histamine H1, alpha1-adrenergic, and muscarinic M1 receptors. Also partial agonist at serotonin 5-HT1A and dopamine D2 receptors (depending on dose).
Partial agonist at D2 and 5-HT1A receptors; antagonist at 5-HT2A and α1B/α2C adrenergic receptors.
Immediate release: 25-100 mg orally twice daily, titrated as needed up to 400-800 mg/day divided twice daily. Extended release: 50-200 mg orally once daily, titrated up to 400-800 mg/day once daily.
2 mg orally once daily initially; increase to 4 mg once daily no sooner than week 2; target dose 4 mg once daily; range 2-4 mg once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 6-7 hours (quetiapine) and 9-12 hours for the active metabolite norquetiapine; with extended-release formulation, effective half-life is ~7 hours due to slower absorption. Clinical steady-state achieved within 2 days.
Terminal elimination half-life is approximately 19–23 days for brexpiprazole and its major metabolite DM-3411, requiring up to 2–3 months to reach steady state.
Renal: 73% (20% unchanged, remainder as metabolites); Fecal: 21%; Approximately 5% excreted in feces as unchanged drug.
Approximately 25% of the dose is excreted in urine as unchanged drug and metabolites; about 54% is excreted in feces. Renal excretion of unchanged drug is minor (<1%).
Category A/B
Category C
Atypical Antipsychotic
Atypical Antipsychotic